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ABSTRACT 
Alanine scanning mutagenesis was employed to determine the structural epitopes of 
preptin; a newly discovered polypeptide found on the proinsulin-like growth factor II. The 
alanine scanning mutagenesis was accomplished by the use of, cloning, affinity chromatography, 
gel electrophoresis, gene sequencing, and mass spectra. However, due to inconclusive results, 
more research is required before the epitopes can be elucidated. 
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A. Diabetes and Cancer 
Diabetes and cancer are two leading causes of death in the United States, and recent 
epidemiological data suggest that people with diabetes are at an elevated risk for most cancers. 
When viewed separately, these diseases have a devastating effect on the quality of life of and 
place a huge economic burden on the American population. Diabetes was ranked as the seventh 
leading cause of American deaths in 2010. It was listed as the underlying cause of death for 
69,071 Americans and was mentioned as a contributing factor for an additional 234,051 deaths.1 
In addition, diabetes carries with it the risk for a host of complications including hypertension, 
dyslipidemia, heart attack, stroke, blindness, kidney disease, and amputations.‘While diabetes 
can be a costly and potentially deadly disease, many of the acute symptoms and effects can be 
alleviated by current therapies. In contrast, cancer remains a devastating disease and was 
responsible for more than 595,000 deaths in 2016. This, coupled with the cost associated with 
treating the more than 1.6 million new cases in 2016, highlights the extreme burden these two 
diseases place on our population. 
Diabetes Mellitus is a group of diseases characterized by elevated blood glucose levels 
resulting from a range of defects in the insulin signaling pathway. The two most common forms 
of diabetes are Type I and Type II. Type I diabetes is responsible for about 5% of total cases 
diagnosed and is characterized by defects in insulin production so that the body cannot meet 
glycemic demand.2,3 In contrast, type II diabetes occurs when the body becomes “insulin 
resistant” resulting in an abnormally high blood sugar concentration.4 As the disease progresses, 
the pancreas produces excessive insulin in an attempt to combat the rising blood sugar levels. 
However, the pancreas is not able to keep up and may eventually cease producing insulin 
entirely.4 
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Much like diabetes mellitus, cancer is a broad term for many specific diseases which 
share characteristics. The most prominent of these characteristics is the uncontrolled growth and 
spread of cells resulting from both internal and external factors. These factors can act either 
together or sequentially, and the instigating event may occur years before the detection of 
symptoms.3,3 
Although the link between diabetes and cancer has not been fully elucidated, there is a 
large body of epidemiological data which would suggest a relationship between the two 
disorders.6'9Diabetes has been associated with a higher risk for liver, pancreas, endometrium, 
colon/rectum, breast, and bladder cancers.7The links between cancer and diabetes may also be a 
result of shared risk factors such as aging, diet, obesity, and physical inactivity.7 In addition to 
these shared risk factors, an increased risk of some cancers has been associated with diabetes 
therapies.7 
For decades research has shown a strong association between obesity and type II 
diabetes. However, it was only in recent years that a link between obesity and cancer was more 
firmly established.7’8 Higher metabolic activity generally associated with excess caloric states 
such as those experienced during obesity can cause tumorigenesis particularly through the 
production of radical oxidative species.8 Further epidemiological evidence has shown links 
between obesity and liver, gallbladder, and pancreatic cancers.9 
B. Preptin 
With the prevalence of these diseases in today’s life, it is important for us to understand 
the metabolic pathways involved in these processes. To this end, a better understanding of the 
structure-activity relationship was sought for the newly discovered hormone, Preptin, which has 
been shown to participate in both mitogenic and metabolic processes. Preptin is a 34-amino acid 
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peptide (3948 Da) corresponding to residues 69-102 of the proinsulin-like growth factor IIE- 
peptide (pro-IGF-IIE). Insulin-like growth factor II (IGF-II; also known as somatomedinA) is 
cleaved into three chains: IGF-II, IGF-II Ala-25 Del, and Preptin.2 
I Murine pro 
IGF-II 
1 1 1 1 | 
Figure 1: Preptin Sequence. The proinsulin-like growth factor which is cleaved into IGF-II, Preptin, and an E- 
peptide. 
Preptin is primarily secreted by kidneys, liver, pancreas, salivary gland, and mammary 
tissue.10 Its main biological and psychological effects are an increase in cell differentiation and 
activity of osteoblasts, regeneration of bone density, limiting of glucose production in the liver, 
modulation of insulin sensitivity, and regulation of energy homeostasis.10 Preptin undergoes 
glucose-mediated co-secretion with and is a physiological amplifier of insulin.2 It has been 
shown that synthetic preptin causes an increase in insulin secretion from glucose-stimulated 
(3TC6-F7 cells in a saturable manner.2 
In addition to its metabolic activity preptin also possesses osteogenic properties. Preptin’s 
osteogenic properties were found to require only the first eight residues which promote increased 
bone growth by increasing the survival rate and proliferation of osteoblasts in both in vitro and in 
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v/vostudies.11 An uncontrolled increase in osteoblast proliferation and survival over time could 
lead to a cancerous condition. In addition to its osteogenic properties, preptin has been 
implicated in the pathology of gestational diabetes. Its association with both osteogenic and 
metabolic functions is further highlighted by its co-expression with IGF-II, which has been 
shown to be upregulated in some cancers.12 
The goal of this work is to better understand the structure-activity relationship of preptin 
using alanine scanning mutagenesis of the peptide chain at positions 21-24. As noted above, the 
first eight residues have been shown to be responsible for preptin’s osteogenic properties, 
therefore our interest primarily lies in the other half of the polypeptide chain.11 Positions 21, 22, 
and 24 are phenylalanine residues which possess large hydrophobic centers that could be used 
for interaction with a hydrophobic pocket on the target receptor. Position 23 is a lysine which has 
a long basic side chain that could have significant interaction with the receptor. 
C. Alanine Scanning Mutagenesis 
Protein libraries are powerful tools in determining the relationship between structure and 
function for proteins. 14Protein libraries are generated through mutagenesis of wild-type proteins 
at specific residues.1’These mutations make it possible to probe the contributions of each 
individual amino acid to the function of the polypeptide. 14A special type of protein library, an 
Alanine scanning mutagenesis library, has been used to gain insight into important biological 
systems such as the binding of human growth hormone (hGH) to hGH-binding protein, CD4- 
binding to HIV-gpno, elucidation of the enzymatic activities of kinases, and determination of 
lysosome stability, just to name a few. Alanine scanning mutagenesis is a method in which 
alanine is systematically substituted for native residues in a step-wise manner. 14Alanine 
effectively allows for the removal of all side chain atoms pass the beta carbon. Additionally, 
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alanine can be introduced without fear of inducing increased conformational flexibility in the 
protein backbone as it does not have a preference for unusual dihedral backbone angles. 
Replacing the native residue with alanine facilitates an inference into the role of the native side 
chain’s effect on the activity of the protein. Through alanine scanning mutagenesis it is possible 
to provide a detailed map of functional epitopes. However, this process is laborious. For 
recombinant proteins, each alanine mutant must first have its gene sequence synthesized or 
amplified, and it must be cloned into an expression vector. The vector is then used to generate at 
least two cell lines, one of which is used for protein production. After protein expression, the 
gene product must be purified and sometimes refolded. 
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A. Overview 
Recombinant DNA technology was employed to express preptin and preptin analogs in E 
coli. Gene fragments encoding for preptin and its analogs were designed using a free translation 
program at ExPasy.org. Synthetic recombinant DNA was cloned into a commercially available 
vector and fusion proteins were isolated using affinity and size exclusion chromatography. 
B. Plasmid Selection 
A syntheticplasmid (pD444-SR) was purchased from ATUM and offered ampicillin resistance, a 
mutated pUCori replication site, lacl regulation gene, a T5 derived promoter, and a strong 
ribosomal binding site.1:The ampicillin resistance gene encodes for a beta-lactamase which is 
secreted into the periplasmic space. This beta-lactamase catalyzes the hydrolysis of the beta- 
lactam ring in ampicillin allowing for the selection of E. coli transformed with this plasmid as 
they exhibit ampicillin resistance of up to 100 pg/ml. The mutated pUCori replication site is 
derived from E. coli plasmid pBR322 and allows for greater than 500 copies of plasmid per cell 
during amplification. The lacl regulation gene codes for a repressor that binds tightly to a short 
DNA sequence just downstream of the beginning promoter in LacZ. This site is known as a lac 
operator and reduces transcription by interfering with the binding of RNA polymerase. The lac 
operon provides tighter repression. It also allows controlled expression by the addition of 
Isopropyl p-D-l-thiogalactopyranoside (IPTG) to the growth media. IPTG binds to the above- 
mentioned repressor in the lac operon site, causing conformational changes in the repressor 
which results in its release. The strong ribosomal binding site (RBS) allows for the RNA 
translation into protein after transcription from DNA by RNA polymerase. These pre¬ 
incorporated tools made pD444 - SR an excellent choice for our plasmid. 
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Figure 2: Synthetic Plasmid. The pD444-SR vector which offers Ampicillin resistance, a mutated pUCori 
replication site, lacl regulation gene, a T5 derived promoter, and a strong ribosomal binding site are indicated. 
C. Gene Construction 
A series of DNA inserts were designed to be incorporated into the syntheticplasmid. 
These inserts encode for an N-terminus six histidine nickel affinity tag, green fluorescent protein 
(GFP), Tobacco Etch Virus protease (TEV) cleavage site, and one of the four preptin alanine 
mutants. The six residue histidine tag provides the ability to isolate the fusion from the cell lysate 
using nickel affinity chromatography. GFP allows for real-time tracking of the fusion during 
chromatography. A TEV cleavage site between GFP and preptin allows for the removal of the 
fusion partner from the target protein.16 
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15 Base Pair Overlap 
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Figure 3:DNA Insert/Plasmid Complementarity. Above shows how each end of the linear plasmid and DNA 
insert share the same complementary 15 base pair sticky ends after being acted upon by the In-Fusion® HD enzyme. 
The nicked plasmid is repaired by the bacteria after transformation. 
The cleaved GFP and TEV can be separated from the target protein by a second round of nickel 
affinity chromatography. The insert was also designed to have a 15 base pair overlap with the 
insertion site of the digested pD444-SR plasmid. These unique 15 base pair complementary 
sequences are required for use of the In-Fusion® FID Cloning Kit (Clonetech). This cloning kit 
uses a proprietary enzyme which degrades a single strand of double-stranded linear DNA by 15 
residues allowing for interaction between built-in complementary ends of the properly oriented 
open plasmid and inserts.17 The 15 base pair interaction is enough to hold the plasmid and DNA 
insert together during transformation into competent cells. Once transformed the cell repairs the 
sugar-phosphate backbone closing the circular plasmid with the insert incorporated. 
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D. Selection of Expression & Amplification Systems 
Escherichia coli (E. coli) was chosen for amplification and expression as it provides 
several advantages over other options.18 The E. coli system provides fast growth kinetics, 
(doubling time-20 minutes) and the ability to reach a stationary phase in only a few hours. 
Furthermore, cell densities, approaching 200 g dry cell weight per liter can be achieved. 18Many 
strains of E. coli have been designed for various applications, of these the DNA amplification 
strain E. coli(DH5a) and protein expression strain E. coli(BL21) were selected. The DH5astvmn 
is commonly used for amplification and has the in vivo ability to recombine heterologous DNA 
fragments with homologous ends.19 E. coli(DH5a) allows for the amplification of plasmid DNA. 
Amplified plasmids were introduced into E. coli(BL21)ce\\s for protein expression. 
E. Plasmid Amplification 
Cloning of the alanine mutants of preptin (21-24) required a large amount of the linear 
plasmid. To accomplish this the parent plasmid was used to transform chemically competent E. 
coli(DH5a) cells. Transformation and growth conditions are described in following sections. 
Plasmid extraction was accomplished by use of the PromegaPureyieldMiniprep kit. An 
alternative protocol was used, which allowed for isolation of plasmid DNA from larger culture 
volumes. This was necessary as the normal protocol did not yield sufficient DNA to support 
automated sequencing. An aliquot (1.5 mL) of an overnight culture was placed into a 
microcentrifiige tube and centrifuged for 30 seconds to collect the cell pellet. The supernatant 
was then discarded, and an additional aliquot (1.5 mL) of culture was added to the 
microcentrifuge tube. The sample was centrifuged under the same conditions, with subsequent 
discarding of the supernatant. The resulting cell pellet was then thoroughly resuspended in 600 
pL of TE buffer, before adding 100 pL of cell lysis buffer (blue) and mixed by inverting the tube 
six times. 350 pL of cold (4-8°C) neutralization solution was then added and mixed thoroughly 
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by inversion. The resulting sample was then centrifuged at maximum speed for 3 minutes before 
transferring the supernatant to a PureYield™ Minicolumn. The minicolumn was placed in a 
collection tube and centrifuged at max speed for 15 seconds with the resulting flow-through 
discarded. Endotoxin neutralization solution (200 pL) was then added to the minicolumn and 
centrifuged for an additional 15 seconds at maximum speed. Finally, 400 pL of column wash 
solution was added with subsequent centrifugation for 30 seconds at maximum speed. The 
minicolumn was then transferred to a clean microcentrifuge tube; 30 pL of elution buffer was 
added and allowed to stand on the column for one minute before centrifuging at maximum speed 
for 15 seconds eluting the plasmid. 
F. Plasmid Digestion 
The amplified plasmid sample was then digested with the enzymes XMal and BsrGI-HF 
(New England Biolabs, NEB). The enzymes were introduced simultaneously to the sample 
containing the plasmid in CutSmart buffer (NEB), followed by incubation for two hours at 37°C. 
The enzymes were then deactivated via incubation at 80°C for 30 minutes. 
G. Isolation of the Linearized Plasmid 
Agarose gel electrophoresis was used to confirm complete digestion at the correct 
restriction sites. It is a commonly used method for DNA separation and is achieved by the aid of 
an electric field. Negatively charged DNA molecules migrate away from the cathode (negative 
pole) and towards the anode (positive pole). DNA fragment migration is determined solely by 
molecular weight, with smaller DNA fragments moving faster down the gel than larger ones. 
This allows for both estimates to be made of the size of DNA fragments with respect to DNA 
ladders, and to isolate specific bands by removing them from the gel. These estimates can be 
compared against calculated fragment size to assess endonuclease digestions. Moreover, this 
13 
method can be used to show the presence of DNA and protein contaminants in isolated 
recombinant plasmid samples, or lack thereof. After digestion, the linearized plasmid was 
separated on a 0.8% agarose gel (Invitrogen) with 0.5 pg/mL EtBr. The gel was run in TAE 
buffer with 0.5 pg/mL EtBr at 130 volts. DNA was collected from the gel using the PureLink™ 
Gel Extraction Kit. 
H. In Fusion Cloning 
The In-Fusion® HD cloning kit (Clonetech) was employed to introduce the synthetic gene 
construct into the digested plasmid. 25 pL Linear plasmid was mixed with 1 pL of the synthetic 
insert in the presence of 8 pL In-Fusion® HD enzyme and 6 pL double distilled water. This 
sample was then allowed to incubate for 15 minutes at 50°C. The In-Fusion® reaction mixture is 
then used immediately for transformation. 
I. Transformation of E. coli (DH5a) 
E. coli(DH5a) cells were transformed directly with the In-Fusion® reaction mixture. 
Competent E. coli(DH5a) cells were first thawed on ice before mixing gently. Competent cells 
(50 pL)were transferred into a falcon tube, followed by addition of 2.5 pL in-fusion reaction 
mixture produced above. This solution was placed on ice for 30 minutes before being heat 
shocked at 42°C for 45 seconds. The sample was then placed on ice for one to two minutes 
before the addition of 447.5 pL of warm at 37°C SOC medium. The sample was then incubated 
for an hour with shaking at 37°C. The transformation reaction was then diluted by 1/5 and 100 
pL of the solution was spread on an ampicillin LB-agar plate spiked with IPTG and incubated 
overnight. The following day, a colony that fluoresced under handheld long wave UV light was 
selected and used to inoculate a 4 mL culture in the presence of ampicillin. Once the growth 
reached exponential phase, the culture was used to make a frozen glycerol stock. 
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J. Isolation of Mutated Plasmids 
The mutated plasmids were isolated from E. co//(DH5a) cells as described above. 
K. Determination of Plasmid Purity and Concentration 
Concentration and purity of the isolated plasmid samples were assessed using 
A260/A280 ratio on a NanoDrop™ 2000 spectrophotometer (ThermoFisher Scientific). The 
A260/A280 Ratio refers to a method where spectrophotometric absorbance of a sample is taken 
at both 260 nm and 280 nm and used to relate the concentrations of nucleic acids and proteins in 
a sample.20The extinction coefficients for a 1 pg/ml nucleic acid sample should be 20 and 10 for 
260 nm and 280 nm, respectively.20 This is in contrast to a 1 pg/ml sample of protein, the trend is 
reversed and the extinction coefficients are 0.57 and 1.0 for 260 nm and 280 nm, respectively.20 
These values suggest that a pure sample of nucleic acid would have an A260/A280 Ratio of 2.0, 
whereas a pure protein sample would have a ratio of 0.57, and a mixture of the samples would 
have a value in between. 
L. DNA Sequencing 
Each of the mutated plasmids was sequenced by the Genomics & Sequencing Lab in the 
Department of Entomology and Plant Pathology, College of Agriculture at Auburn University. 
M. Transformation of E. coli BL21 
E. coli(BL21) cells were transformed with the purified plasmid from the E. coli(DH5a) 
miniprep using the same method as described previously. The transformation reaction was 
spread on an ampicillin LB-agar plate spiked with IPTG and incubated overnight. The following 
day, a colony that fluoresced under handheld long wave UV light was selected and used to 
inoculate a 4 mL culture in the presence of ampicillin. Once the growth reached exponential 
phase, the culture was used to make a frozen glycerol stock. 
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N. Protein Expression 
The newly established E. coll (BL21) cell lines were used to express the GFP-preptin 
fusions. A sample of the frozen stock was used to inoculate an overnight starter culture 
(incubated at 37°C, with shaking). The following morning, the starter culture was used to 
inoculate a 1 L culture which was incubated at 37°C with shaking until an optical density at 600 
nm (ODaoo) of between 0.6 and 0.8 was achieved. The culture was cooled to room temperature 
and 1 mL IPTG was added. The culture was incubated at 18°C overnight with shaking. The 
following day the cells were collected via centrifugationusing the GSA rotor for 15 minutes at 
5000 RPMs. The resulting pellet was resuspended in NPI-0 (recipe in Table 1) before being 
lysed. A sonicator was used, with a 2 second on 1-second rest cycle for 9 minutes while the 
sample was in an ice bath to lyse the cells. The resulting solution was centrifuged in a Sorval 
RC-5B instrument with an SS-34 rotor for 20 minutes at 15,000 RPMs and the supernatant 
collected. 
O. Nickel Affinity Chromatography 
Nickel affinity chromatography was used to separate the target protein from the unwanted 
native proteins, and to remove the digested fusion tag from the target protein in later steps. As 
mentioned previously the fusion protein was designed with a six-histidine affinity tag. This tag 
chelates with immobilized nickel on a gel support. Proteins immobilized by the nickel affinity 
chromatography can be later removed by the addition of imidazole or with solutions of lowering 
pH.21In this way the target protein can be purified from all non-histidine tag proteins in a single 
step. This also allows for the later separation of the histidine-tagged fusion protein partner and 
digestion enzyme from preptin after digestion. Preptin was isolated from the supernatant using 
gravity flow over Ni-NTA Agarose resin (Qiagen). The column was washed with increasing 
16 
concentrations of imidazole (see table 1). The GFP fusion was eluted with NPI-500 until the 
absorbance at 280 nm was less than 0.05%. 
Table 1: Nickel Affinity Chromatography Purification Buffers. Below is a list of the buffers used throughout 
this experiment during nickel affinity purification stage. 
Buffer fNaCll [NaFbPCUl [Tween 20] [Imidazole] pH 
NPI-0 300 mM 50 mM .05% (v/v) 0 pH 8 
NPI-10 300 mM 50 mM .05% (v/v) 10 mM pH 8 
NPI-20 300 mM 50 mM .05% (v/v) 20 mM pH 8 
NPI-40 300 mM 50 mM .05% (v/v) 40 mM pH 8 
NPI-500 300 mM 50 mM .05% (v/v) 500 mM pH 8 
NPI-0 No PEG 300 mM 50 mM 0 0 pH 8 
NPI-10 No PEG 300 mM 50 mM 0 10 mM pH 8 
NPI-20 No PEG 300 mM 50 mM 0 20 mM pH 8 
NPI-40 No PEG 300 mM 50 mM 0 40 mM pH 8 
NPI-500 No PEG 300 mM 50 mM 0 500 mM pH 8 
P. Purification: Sephadex G 25 Size Exclusion Chromatography 
Although nickel affinity chromatography allows for the easy separation of the target 
protein from the rest of the native proteins found in E. coli. It introduces a large amount of 
imidazole and other salts to the sample. Thus a desalting step was required. Sephadex G 25 size 
exclusion chromatography provides a convenient desalting method. This method relies on porous 
beads of dextrose that construct two major spaces, the gaps between the beats (void volume) and 
the pores within them (pore volume).22 The void volume is significantly smaller than that of the 
pore volume and so if the size difference between the molecules that are to be separated is large, 
such that the smaller molecules can enter the pore volume. Then the larger molecules which 
cannot enter the pore volume will be eluted faster because their exclusion provides them a 
shorter volume in which to traverse. This allows for the quick and efficient separation of proteins 
from salts and small molecules such as Imidazole. Further, because of the incorporated GFP, 
tracking the progress of the fusion protein over the course of chromatography becomes as simple 
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as exposing fractions to UV light in order to see if they fluoresce. Samples which fluoresce can 
be pooled and later lyophilized. The preptin sample was then desalted via size exclusion 
chromatography on a Sephadex G-25 coarse resin (Sigma Aldrich) to facilitate a buffer 
exchange. Fractions were collected every thirty seconds and their absorbance at 280 nm 
measured; samples containing high absorbance were pooled and flash frozen in a dry 
ice/methanol mixture. The frozen sample was then lyophilized and stored at 4°C. 
Q. Expression of TEV Protease 
A starter culture of Tobacco etch virus protease (TEV) BL21-pnk793-000-009 (Addgene) 
was prepared by inoculating 100 mL of LB with 10 pL ampicillin and 3 pL chloramphenicol. 
The starter culture was incubated overnight at 32°C before being used to start a 1 L growth of LB 
inoculated with 100 pL ampicillin and 30 pL chloramphenicol. This growth was incubated until 
it’s OD 600 was between 0.6 and 0.8 after whichl mL IPTG was added and the sample was 
allowed to incubate overnight at 32°C.The enzyme was purified and stored as described by 
Expression and Purification of Soluble His6 -Tagged TEV Protease.16 
R. Removal of GFP Fusion Tag 
The fusion protein was designed with a TEV restriction site between GFP and preptin. To 
carry out digestion 0.005 g TEV, 100 pL of lOx urea/EDTA (4.0 M urea/.5 mM EDTA), and 100 
pL of lOx TECP (10 mM TECP) were added to 800 pL of the purified fusion sample. The 
reaction was allowed to incubate at 4°C overnight. These samples were subjected to 
Polyacrylamide gel electrophoresis (PAGE), and electrospray time-of-flight mass spectrometry 
to test the validity of the digestion process. 
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S. Resuspension of Precipitate from Cleavage Reaction 
Precipitation was observed during the cleavage reaction. Precipitant was separated from 
the supernatant and subsequently resuspended in a buffer of lOx urea/EDTA and split into two 
samples subjected to strongly basic and acidic conditions, respectively. A serial dilution of both 
samples was performed with one half, one fourth, and one-eighthconcentrations respectively. All 
samples and the supernatant were subjected to standard workup procedures in preparation for 
PAGE. 
T. SDS-PAGE 
Similarly to the extraction of plasmid, a method of characterizing the purity and relative 
mass of the fusion protein samples was required. To achieve this sodium dodecyl sulfate (SDS) 
PAGE was employed. As with all electrophoresis SDS-PAGE takes advantage of the movement 
of negatively charged particles away from the cathode and towards the anode.23 However, 
proteins have a much wider variety of structural configurations due to hydrophobic and 
hydrophilic interactions forming secondary tertiary and even quaternary structures. This hurdle 
can be overcome by use of the detergent sodiumdodecyl sulfate (SDS) which when boiled in 
presence of the protein the natures them and imparts a uniform charge/mass ratio. This uniform 
charge mass ratio imparted by SDS is a result of its hydrophobic carbon chain permeating and 
interfering with the binding of hydrophobic groups causing the denaturation of the protein into a 
random coil coated with negatively charged detergent molecules along the length. This allows 
for the separation based on the mass of proteins found in a complex mixture. Utilizing all of 
these tools it will be possible to test if the E. coli amplification and expression system is capable 
of performing in alanine scanning mutagenesis on preptin in preparation for further research into 
the activity of preptin. Although alanine scanning mutagenesis is a well-established method, and 
the use of E. coli expression systems is likewise well-established, these methods have never been 
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applied to nor used to express preptin or its alanine mutants. Therefore a determination on 
whether or not they are viable methods in the biosynthesis of preptin and preptin’s alanine 
mutants is required. 

A. Rationale 
In the light of a growing body of evidence linking diabetes and cancer, there is an 
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increased demand to unravel the links between these two devastating diseases. With this in mind, 
the goal of this project was to elucidate the role of a prominent hydrophobic patch in the final 
third of the preptin hormone by expressing and testing the alanine mutants. It is expected that the 
information gleaned from these novel analogs will be used to design two preptin derived peptides 
that could elicit separate mitogenic and metabolic processes. Such peptides would provide 
powerful tools for exploring the individual pathways associated with bone growth and insulin 
signaling amplification. Additionally, these molecules could serve as starting points for potential 
treatments of osteoporosis and diabetes. 
The recent discovery of preptin limits the number of available assays for assessing 
activity. Our collaborators at the University of Auckland have established assays using both rat 
and mouse cell lines. To give us the most flexibility we chose to begin our work with the rat 
sequence since it displays activity in both cells lines (human and mouse sequences do not). 
B. Expression of Native Preptin without GFP 
Initial attempts to produce preptin were stymied during the purification phase due to a 
lack of access to a preparative scale HPCL or FPLC system and on-site mass spectrometer. 
Instead, gravity flow nickel affinity and size exclusion chromatography were used in conjunction 
with a standalone fraction collector and bench top UV-Vis spectrophotometer. This process 
proved to be time-consuming and correct identification of the preptin containing samples delayed 
pending off-site mass spectral analysis. 
22 
C. Introduction of GFP 
In order to accelerate the purification steps and allow for initial assessment of purity to be 
carried out in-house, a designer gene fragment was designed that encoded for a removable green 
fluorescent protein tag on the N-tenninus of the preptin mutants. The addition of the GFP tag to 
allowed purifications to be carried out without UV detectors. An inexpensive UV pen light (Bio- 
Rad) was used to track the fusion protein as it moved through the columns. This provided a 
means to identify the pertinent fractions for further use. 
D. Cloning of Fusion Protein 
The In-Fusion*1 HD cloning kit (Clonetech) was designed to provide rapid cloning 
requiring fewer steps than traditional cloning methods. However, cloning of the synthetic gene 
fragments into the PD444-SR plasmid failed more than 50% of the time and required significant 
optimization before correctly transformed cells were identified. The most common result of the 
cloning reactions was the recovery of the original parent plasmid. Significant effort was applied 
to ensuring that the plasmid was completely digested and purified prior to the introduction of the 
synthetic fragment. In all, more than 10 cloning reactions were carried out at a cost of over $500 
before all four mutated plasmids were confirmed. 
E. Sequencing of Plasmids 
Successful cloning reactions were confirmed by sequencing of the amplified plasmids. 
Samples were submitted to the Genomics & Sequencing Lab in the Department of Entomology 
and Plant Pathology, College of Agriculture at Auburn University. Results were analyzed using 
the free sequencing software Chromas (Technelysium). The sequence encompassing the 
mutation site for each mutated gene can be found in Figures 4-7 which confirm the presence of 
alanine mutations at positions 21-24 respectively. 
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Figure 4: Sequencing results for the mutated GFP-Preptin AIa21 gene. Sequencing confirms mutation of the 
codon encoding for phenylalanine at peptide position 21 with the codon for alanine (red box). The reading frame for 
preptin is 577-679. 
Figure 5: Sequencing results for the mutated GFP-Preptin Ala22 gene. Sequencing confirms mutation of the 
codon encoding for phenylalanine at peptide position 22 with the codon for alanine (red box). The reading frame for 
preptin is 576-678. 
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Figure 6: Sequencing results for the mutated GFP-Preptin Ala23 gene. Sequencing confirms mutation of the 
codon encoding for lysine at peptide position 23 with the codon for alanine (red box). The reading frame for preptin 
is 498-597. 
Figure 7: Sequencing results for the mutated GFP-Preptin Ala24 gene. Sequencing confirms mutation of the 
codon encoding for phenylalanine at peptide position 24 with the codon for alanine (red box). The reading frame for 
preptin is 474-576. 
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F. Transformation of E. coli (BI21) 
Successful transformation of E. coli(BL21)vidLS confirmed by the presence of green 
fluorescence from cells plated on plates spiked with IPTG. 
G. Expression of Fusion 
Similarly, expression of the fusion proteins was confirmed by the presence of a strong 
green fluorescence after induction by IPTG. 
H. Nickel Affinity Chromatography 
Isolation of the fusion proteins the supernatant after centrifugation was performed using a 
nickel affinity chromatography. Purification progress was monitored with PAGE. It is worth 
noting that even at the lowest concentrations of imidazole; fluorescence was observed in the 
eluent from the affinity column. It is postulated that this is a result of partial misfolding of the 
poly-histidine containing fusion tag. Despite the loss of some fusion during the affinity 
purification step, a significant amount of product was observed in the final elution as evidenced 
by intense fluorescence and a strong band on the polyacrylamide gel (Figure 8). 
Table 2: Masses of Preptin Target & Fusion Proteins. 
Alanine mutant Mass Replaced residue 
Fusion protein Preptin Ala21 32,483.41 Da Phenylalanine 
Fusion protein Preptin Ala22 32,483.41 Da Phenylalanine 
Fusion protein Preptin Ala23 32,502.41 Da Fysine 
Fusion protein Preptin Ala24 32,483.41 Da Phenylalanine 
Preptin Ala21 3,913.36 Da Phenylalanine 
Preptin Ala22 3,913.36 Da Phenylalanine 
Preptin Ala23 3,932.37 Da Fysine 
Preptin Ala24 3,913.36 Da Phenylalanine 
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Figure 8: Affinity Chromatography Isolation of GFP-Preptin Ala21 Fusion. A sample from the various column 
washes was analyzed by PAGE. From left to right there is a decrease in extraneous proteins as we move to our 
purified product. (Lane 1) contains a ladder, (lane 2) lysis solution, (lane 3) lysis supernatant after centrifugation, 
(lane 4) eluent from wash one, (lane 5) eluent from wash two, (lane 6) eluent from wash three, (lane 7) eluent from 
wash four, and (lane 8) the purified fusion protein. 
Figure 9: Affinity Chromatography Isolation of GFP-Preptin Ala23 Fusion and Post Cleavage Analysis. A 
sample from the various column washes was analyzed by PAGE. AN increase in the migration of the major band is 
evident after treatment with TEV (lane 2) with respect to the untreated sample (lane 4) indicating successful 
cleavage. However, a band corresponding to the preptin peptide (~4 kDa) was not observed. The remaining samples 
are column washes #4 through #1 (lanes 5-8 respectively). With the flow through from column loading (lane 9) and 
the supernatant after cell lysis and centrifugation (lane 10). 
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I. Tobacco Etch Virus Protease Cleavage Reaction 
The purified fusion protein was subjected to treatment with TEV protease to cleave the 
fusion tag from the target peptide. Subsequent analysis by PAGE confirms a shift in the retention 
time of the GFP protein (Figure 9). However, the target peptide was not observed on the gel. It is 
worth noting that a significant amount of non-fluorescing precipitate was produced during the 
cleavage reaction. Subsequently, attempts to solubilize the precipitant in solutions covering a 
range of pH values with and without urea meet with minimal success. Samples which were 
reduced the amount of precipitate were analyzed by PAGE. 
J. Analysis of the Cleavage Reaction Precipitate. 
The precipitant observed after the reaction with TEV was analyzed to see if it contained 
our target peptide. When the solutions were run on a 12% polyacrylamide gel, a smear in the 
proximity of the lOkDa region was observed (Figure 10). However, that mass does not match the 
predicted mass of the target peptides. The samples use subsequently analyzed on a 
polyacrylamide 4-20% gradient gel made by Bio-Rad to resolve the bands found near the bottom 
of the 12% gel (Figure 11). 
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Figure 10: Analysis of TEV Reaction Precipitant by PAGE on 12% gel. The untreated GFP-Fusion is seen in 
(lane 2), but no band is present in the supernatant of the TEV reaction mixture (lane 3) suggesting precipitation of 
GFP. Resuspension of the precipitant in an acidic solution restores a band at the mass expected for cleaved GFP 
(lane 4). No bands corresponding to fusion or cleaved GFP are observed in the sample of precipitant resuspended in 
basic solution. However, a smear in the lOkDa range is observed (lane 5) 
25KD 
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Figure 11: Analysis of TEV Reaction Precipitant by PAGE on a 4-20% gradient gel. A gradient gel was used in 
an attempt to visualize the preptin peptide target (~4 kDa) and the fusion tag on the same gel. The untreated GFP- 
Fusion is seen in (lane 2), but no band is present in the supernatant of the TEV reaction mixture (lane 3) suggesting 
precipitation of GFP. Resuspension of the precipitant in an acidic solution restores a band at the mass expected for 
cleaved GFP and a dark smear centered around 15 kDa (lane 4). No bands corresponding to fusion or cleaved GFP 
are observed in the sample of precipitant resuspended in basic solution. However, a smear in the lOkDa range is 
observed (lane 5). Unfortunately, a no evidence of the preptin product was observed. 
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From these two experiments, it was found that the vast majority of proteins had been 
precipitated out of solution after the TEV cleavage reaction (lane 3 in figure 10 and 11). When 
exposed to a low pH solution the majority of the proteins were resuspended; this includes what 
was presumed to be the fusion partner GFP. However, when exposed to a high pH buffer only 
proteins with masses below 15kDa were resuspended. This result was confounding, under both 
conditions, the precipitant had seemingly been dissolved, and yet the electrophoresis showed 
distinctly different proteins within the acid and base samples respectively. To test these 
incongruities an additional cleavage reaction on GFP-preptin Ala2’fusion was performed and 
analyzed by PAGE on a 4-20% gradient gel (Figure 12). 
Figure 12: Analysis of second TEV reaction precipitant by PAGE on a 4-20% gradient gel. Unlike the first two 
reactions, neither the fusion nor cleaved GFP was detected in any of the samples after reaction with TEV protease. 
Light bands in the regions of the smears in figures 10 and 11 were detected, but do not correspond to the expected 
mass for preptin. 
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Although a tight band below 10 kDa was observed, there was still a distinct absence of 
any larger proteins found in the samples tested. To test the validity of these results the digestion 
reaction on GFP-preptin Ala21 fusion was repeated with six times the volume. Because the 
precipitant was thought to contain the vast majority of the proteins formerly in solution, this 
increase in volume was intended to increase the concentration of proteins once redissolved. In 
addition to these modifications, the precipitate from the TEV reactions was dissolved in acidic 
and basic solutions, and the precipitant that did not dissolve in the acid solution was dissolved in 
a basic solution (Figure 13). 
Figure 13: Analysis of precipitant from the TEV reaction in acid and base solutions. The GFP-preptin Ala21 
fusion is in (lane 1). (Lane 3)is supernatant from the TEV protease reaction. Unlike previous attempts, GFP and/or 
fusion is observed in the supernatant. A faint band at approximately the mass of preptin was observed in the 
precipitant sample dissolved in basic solution. 
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K. Mass Spectrometry Analysis of TEV Reaction. 
Samples from the three TEV cleavage reactions were tested using liquid chromatography 
time-of-flight electrospray mass spectrometry (LC-MS). Although both the raw and de- 
convoluted mass spectra are presented, the discussion will be restricted to the de-convoluted 
mass spectra when available. 
1. Precipitate from TEV Cleavage of GFP-preptin-Ala2lin Basic Solution. 
The absence of a preptin band in the TEV cleavage reaction supernatant coupled with the 
appearance of a low molecular weight smear when the precipitant was dissolved in a basic 
solution (PB) suggested that the sample should be analyzed by LC-MS. 
The chromatogram for PB showed a complex elution peak centered around 5.25 minutes 
when running on an isocratic gradient of acetonitrile (Figure 14). The raw data was compared to 
the mass of preptin-Ala21, and the predicted degradation masses. This list included mass to 
charge ratios up to ten, and yielded 54 peaks of interest, with masses less than 2 Da from the 
predicted masses: 13 peaks at 0.265 minutes (Figure 15), 8 peaks at 5.484 minutes (Figure 16), 
and 21 peaks at 12.785 minutes (Figure 17). The elution peak at 0.265 minutes produced two m/z 
values corresponding to the fifth and sixth charge states of preptin which suggested that preptin 
did not stick to the column and eluted during loading. The remaining peaks had several m/z 
signals that could be attributed to enzymatic cleavage products of preptin. However, upon further 
inspection, it was determined that the sample had significant contamination of polyethylene 
glycol (PEG) that was carried over from the lysis buffer which contained Tween8 20. 
The second round of expression and purification of GFP-preptin-Ala21 was carried out 
without the addition of Tween® 20. The precipitant from the TEV cleavage reaction (PB w/o 
PEG) was submitted for analysis by LC-MS and an acetonitrile gradient was used to elude the 
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polypeptides from the reverse phase column. This resulted in a shift of the majority of the signal 
to the column wash portion of the run (Figure 18). The chromatography peak at 5.751 minutes 
produced two m/z signals (14,308 Da and 28,616 Da) that could represent the +1 and +2 peaks 
for a mutated GFP (Figure 19). The cleaved GFP with the polyhistidine tag has an expected mass 
of 28,588.06 Da, or 28 Da less than observed. This discrepancy suggests a mutation in the GFP 
region of the gene. 
More interestingly, two m/z signals (3,971 Da and 7939 Da) were observed at 6.593 
minutes (Figure 20). The smaller signal is approximately 57 Da heavier than the expected mass 
of preptin-Ala21 (3,913.36 Da). This is suggestive of a mutation in which glycine is added 
somewhere on the preptin-Ala21 mutant. The larger peak could be the dimer of this glycine heavy 
mutant. However, there is no previous evidence that preptin dimerizes. 
2. Supernatant of GFP-preptin-Ala21 TEV protease reaction supernatant. 
The failure to observe the preptin analog in the PB samples prompted the analysis of the 
TEV cleavage reaction supernatant to determine if the target peptide was present but not 
observed by PAGE due to the small size. The supernatant from a fresh TEV cleavage reaction 
(without PEG) was analyzed by LC-MS using an acetonitrile gradient (Figure 21). Despite the 
presence of several peaks at low acetonitrile concentrations, no m/z values indicative of the 
preptin analog product were observed. A 32,461 Da peak was observed at 6.065 mins. (Figure 
22), which is 22.4 Da less than the expected for the cleaved fusion tag. 
Two masses that could be the cleaved fusion tag were observed in the PB and supernatant 
samples. However, they differ from the expected mass and do not agree with each other. The 
significance of these observations is unclear at this time. Additionally, the preptin analog was not 
identified in any of the samples. 
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3. Supernatant of GFP-preptin-Ala23 TEV protease reaction supernatant. 
Analysis of the GFP-preptin-Ala21 TEV protease reactions yielded an m/z signal that 
matched the target peptide mass plus 57 Da. It was unclear if the mass represented an 
unintentional preptin mutation or if it was an unidentified bacterial peptide. To differentiate 
between the two possibilities, the GFP-preptin-Ala23 mutant was expressed, purified, and 
subjected to TEV protease. The K23A analog has a mass that is approximately 10 Da heavier 
than the phenylalanine to alanine analogs. If the previously observed mass of 3,913.36 Da was 
observed it would rule out a glycine addition and indicate the presence of an unidentified 
bacterial peptide. 
The fusion protein sample before and after TEV cleavage was analyzed by LC-MS. The 
untreated sample showed two broad overlapping peaks centered around 9 mins (Figure 12). The 
chromatogram for the TEV reaction mixture (Figure 24) was markedly different than the one for 
the GFP-preptin-Ala21 cleavage reaction, but strikingly similar to the sample before reaction with 
TEV. While there were numerous difference in the m/z profiles for the untreated and treated 
samples, neither the 3,913.36 Da nor the preptin-Ala23 signals were observed. 
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Figure 14: Chromatogram of PB(isocratic elution).A convoluted elution peak centered around 5.25 minutes is 
evidence of a complex protein mixture. The large signal seen starting in minute 11 are attributed to washing the 
column. 
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Figure 15: Spectrum of polypeptides eluted from the chromatography column at 0.265 minutes from the PB 
sample. 
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Figure 16: Spectrum of polypeptides eluted from the chromatography column at 5.484 minutes from PB 
sample. 
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Figure 17: Spectrum of polypeptides eluted from the chromatography column at 12.785 minutes from the 
reaction of GFP-preptin Ala21 with TEV protease. 
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Figure 18: Chromatogram of PB without PEG (gradient elution). The majority of polypeptide signal was shifted 
to the column wash region of the gradient run. 
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Figure 19: Mass Spectrum at 5 mins for PB w/o PEG. The peak at 5.048 minutes contained two m/z signals that 
could correspond to a mutated GFP fusion partner. 
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Figure 20: Mass Spectrum at 6.953 mins for PB w/o PEG. The peak contained two m/z signals that could 
correspond to a glycine heavy preptin-Ala21 mutant and its dimer. 
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Figure 21: Chromatogram of GFP-preptin-Ala21 TEV cleavage reaction supernatant. The chromatograph 
showed an increase in the number of small and/or hydrophilic peptide signals at low acetonitrile concentrations. This 
is in contrast to the PB samples. 
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Figure 22: Mass Spectrum at 6.065 mins for TEV cleavage reaction supernatant. The peak at 32,461 Da lighter 
by 22.4 Da than the expected mass for the cleaved fusion tag. 
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Figure 23: Chromatogram of GFP-preptin-Ala23 fusion sample before TEV cleavage. 
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Figure 24: Chromatogram of GFP-preptin-Ala23 TEV cleavage reaction supernatant. The chromatograph was 
markedly different than the one observed for the Ala21 mutation but very similar to the untreated sample. 
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A. Conclusions 
Although a clear picture of what is going on in the biosynthesis of these for alanine 
mutants remains elusive, given time these problems can be overcome and the initial goal of 
performing an alanine scanning mutagenesis using an E. coli expression system will be realized. 
In the interim, however, only a few things can be stated with certainty, several possibilities can 
be suggested, and the next steps in furthering the research can be mapped for future researchers. 
Based on the sequencing there is a fair degree of certainty data that no mutations occurred prior 
to the transformation of E. coli BL 21 cells. If mutations occurred, it must have been after this 
point, if at all. There is no major evidence to suggest a mutation of the plasmid. It is fairly certain 
that the fusion partner GFP was produced in an active form based on fluorescence observed 
under UV light. Based on the mass observed for TEV there is fair confidence that this protein 
was produced. 
B. Future Work 
Based on the data there are several suggestions that can be made as to what may have 
occurred in the samples. The precipitant seems to contain a large portion of the proteins found 
after the reaction has taken place. Although the early analysis of the first mass spectra data was 
more or less thrown out, the idea of protease digesting the fusion protein is still a valid one. The 
observations in later mass spectra suggest the presence of an extra glycine which may have 
occurred during or after translation, as well as other unknown modifications to the GFP fusion 
partner; assuming the masses mentioned above belong to the fusion partners and not native 
proteins still retained in the sample. The final mass spectra also suggest the possibility of 
protease digestion prior to the reaction using TEV. 
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